Storebo O, Pedersen N, Ramstad E, Kielsholm M, Nielsen S, Krogh H
Cochrane Database Syst Rev. 2018; 5:CD012069.
PMID: 29744873
PMC: 6494554.
DOI: 10.1002/14651858.CD012069.pub2.
Li L, Wang Y, Uppoor R, Mehta M, Farchione T, Mathis M
J Pharmacokinet Pharmacodyn. 2017; 44(3):245-262.
PMID: 28214989
DOI: 10.1007/s10928-017-9513-5.
Lyauk Y, Stage C, Bergmann T, Ferrero-Milliani L, Bjerre D, Thomsen R
Clin Transl Sci. 2016; 9(6):337-345.
PMID: 27754602
PMC: 5351003.
DOI: 10.1111/cts.12423.
Baskin B, Dwoskin L, Kantak K
Pharmacol Biochem Behav. 2015; 131:51-6.
PMID: 25643872
PMC: 4369437.
DOI: 10.1016/j.pbb.2015.01.019.
Yang X, Morris S, Gearhart J, Ruark C, Paule M, Slikker Jr W
PLoS One. 2014; 9(9):e106101.
PMID: 25184666
PMC: 4153582.
DOI: 10.1371/journal.pone.0106101.
A review of psychostimulant-induced neuroadaptation in developing animals.
Carrey N, Wilkinson M
Neurosci Bull. 2011; 27(3):197-214.
PMID: 21614102
PMC: 5560359.
DOI: 10.1007/s12264-011-1004-x.
Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine.
Kuczenski R, Segal D
J Neurosci. 2002; 22(16):7264-71.
PMID: 12177221
PMC: 6757883.
DOI: 20026690.
Pharmacokinetics and clinical effectiveness of methylphenidate.
Kimko H, Cross J, Abernethy D
Clin Pharmacokinet. 2000; 37(6):457-70.
PMID: 10628897
DOI: 10.2165/00003088-199937060-00002.
Enantioselective pharmacokinetics of dl-threo-methylphenidate in humans.
Srinivas N, Hubbard J, Korchinski E, Midha K
Pharm Res. 1993; 10(1):14-21.
PMID: 8430051
DOI: 10.1023/a:1018956526016.
The persistence of stimulant effects in chronically treated children: further evidence of an inverse relationship between drug effects and placebo levels of response.
Gualtieri C, Hicks R, Mayo J, Schroeder S
Psychopharmacology (Berl). 1984; 83(1):44-7.
PMID: 6146156
DOI: 10.1007/BF00427420.
The effects of background illumination and stimulant medication on smooth pursuit eye movements of hyperactive children.
Bylsma F, Pivik R
J Abnorm Child Psychol. 1989; 17(1):73-90.
PMID: 2926024
DOI: 10.1007/BF00910771.
Effects of d-amphetamine and methylphenidate on hyperactivity produced by neonatal 6-hydroxydopamine treatment.
Luthman J, Fredriksson A, Lewander T, Jonsson G, Archer T
Psychopharmacology (Berl). 1989; 99(4):550-7.
PMID: 2594922
DOI: 10.1007/BF00589907.
Use of methylphenidate for attention deficit hyperactivity disorder. Mental Health Committee, Canadian Paediatric Society.
CMAJ. 1990; 142(8):817-8.
PMID: 2322913
PMC: 1451911.
Neonatal dopamine lesion in the rat results in enhanced adenylate cyclase activity without altering dopamine receptor binding or dopamine- and adenosine 3':5'-monophosphate-regulated phosphoprotein (DARPP-32) immunoreactivity.
Luthman J, Lindqvist E, Young D, Cowburn R
Exp Brain Res. 1990; 83(1):85-95.
PMID: 1981564
DOI: 10.1007/BF00232196.
Pharmacokinetic and pharmacodynamic data collection in children and neonates. A quiet frontier.
Gilman J, Gal P
Clin Pharmacokinet. 1992; 23(1):1-9.
PMID: 1617855
DOI: 10.2165/00003088-199223010-00001.
